What Does Celgene's Failed Trial Mean for Investors? Motley Fool Biogen Idec (NASDAQ: BIIB ) and Roche offer rituximab as a first-line combination treatment, while Sanofi offers alemtuzumab as a second line treatment. Rituximab brought in $7.2 billion in sales in 2012 -- making it one of the most successful drugs in ... |
